Pro-Con Debate

Fibrinogen Concentrate or Cryoprecipitate for Treatment of Acquired Hypofibrinogenemia in Cardiac Surgical Patients

Nadia B. Hensley, MD; Michael A. Mazzeffi, MD, MPH, MSc, FASA


Anesth Analg. 2021;133(1):19-28. 

In This Article

Fibrinogen Concentrate Advantage: Reduced Risk of Transfusion Adverse Events

With any allogeneic transfusion, including cryoprecipitate, there is a risk of alloimmunization and allergic transfusion reaction.[32] Fibrinogen concentrate undergoes viral inactivation processing, which also removes blood and human leukocyte antigen (HLA) antibodies and antigens and significantly reduces the risk of immunological transfusion reaction.[12] Transfusion-associated circulatory overload (TACO), transfusion-related acute lung injury (TRALI), and allergic transfusion reactions remain significant risks of allogeneic blood transfusion and are associated with increased health care cost, morbidity, and mortality.[33,34]